Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2011. The report serves as a notification to the market regarding the Company's total voting rights and capital structure in conformity with Disclosure and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a capital structure notification rather than a financial performance report.
Material Changes
The filing details the Company's issued share capital as of January 31, 2011:
- Total issued Ordinary shares: 5,670,652,447 (25p each).
- Treasury shares held: 474,194,158.
- Total voting rights: 5,196,458,289.
No other material changes to operations or financial position are disclosed in this text.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or unusual items. Its sole purpose is to provide the denominator for shareholder calculations regarding notification requirements under the Financial Services Authority's Disclosure and Transparency Rules.
Key Facts for Investor Verification
- Verify the total voting rights count of 5,196,458,289 for compliance with disclosure thresholds.
- Confirm the number of treasury shares (474,194,158) held as of January 31, 2011.
- Note that this filing does not contain financial performance data; refer to Form 20-F for annual results.